Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma

Pulmonologiya - Russian Federation
doi 10.18093/0869-0189-2018-28-1-50-60
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Scientific and Practical Reviewed Journal Pulmonology

Related search

Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma

Prescriber
Pharmacology
2017English

Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2020English

Prs54 - Cost-Effectiveness Analysis of Reslizumab for Patients With Severe Eosinophilic Asthma Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting B2-Agonists in South Korea

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Severe Eosinophilic Asthma: A Roadmap to Consensus

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Benralizumab for the Treatment of Severe Eosinophilic Asthma

Prescriber
Pharmacology
2018English

A High Proportion of Exacerbation-Prone Patients With Uncontrolled Eosinophilic Asthma Receiving IV Reslizumab Experienced Zero Asthma Exacerbations Through 52 Weeks (Wks) of Treatment

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Pharmacy Reimbursement and Pharmacoeconomic Aspects of Therapy of Bronchial Asthma

Pharmacoeconomics: theory and practice
2018English

Pharmacoeconomic Analysis of Using Biological Agents for Uncontrolled Moderate-To-Severe Atopic Asthma in the Russian Federation

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy